Product Images Ketorolac Tromethamine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Ketorolac Tromethamine NDC 0404-9998 by Henry Schein, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Image1.jpg - Image1

Table 1 provides approximate average pharmacokinetic parameters for Ketorolac Tromethamine administered orally, intramuscularly, and intravenously. It includes parameters such as bioavailability, time to maximum concentration (T max), maximum concentration (C max), as well as steady-state levels at different dose levels. The table offers insights into the pharmacokinetics of Ketorolac Tromethamine for doses ranging from 10mg to 60mg, showcasing values for bioavailability, C max, C min, and volume of distribution.*
Image2.jpg - Image2

This text contains information related to pharmacokinetic studies, including data on dose metabolized, excretion in feces and urine, plasma protein binding, time-to-peak plasma concentration, peak and trough plasma concentrations, volume of distribution, and average plasma concentration in different types of pharmacokinetic studies. The values presented are derived from studies conducted in normal volunteers and include information on the recommended single dose and mean simulated values from observed data.*
Image4.jpg - Image4

This text presents a list of gastrointestinal (GI) experiences, including symptoms like abdominal pain, constipation, diarrhea, dyspepsia, flatulence, fullness, ulcers, heartburn, nausea, stomatitis, and vomiting. Other experiences mentioned are abnormal renal function, anemia, dizziness, drowsiness, edema, elevated liver enzymes, headaches, hypertension, increased bleeding time, injection site pain, pruritus, purpura, rashes, tinnitus, and sweating. It provides an overview of potential side effects or symptoms related to a medical condition or treatment.*
Image5.jpg - Image5

This table shows the incidence of clinically serious G.I. bleeding related to age, total daily dose, and history of G.I. perforation, ulcer, bleeding after up to 5 days of treatment with Ketorolac Tromethamine Injection. The data is divided into two groups: A. Adult Patients without History of PUB, and B. Adult Patients with History of PUB. For each group, the percentage of G.I. bleeding is shown based on different age ranges and total daily doses of Ketorolac Tromethamine Injection.*
Image6.jpg - Image6

This is information about Ketorolac Tromethamine Injection USP offered in different concentrations and packaging sizes. The product is available in single-dose vials with varying strengths of 15 mg/mL, 30 mg/mL, and 60 mg/2 mL. Each carton contains 25 vials of the respective concentration.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.